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Endothelial cell activation plays a critical role in regulating leukocyte recruitment during 
inflammation and infection. Based on recent studies showing that acetylcholine and other 
cholinergic mediators suppress the production of proinflammatory cytokines via the 
 
 
 
7 
nicotinic acetylcholine receptor (
 
 
 
7 nAChR) expressed by macrophages and our observations 
that human microvascular endothelial cells express the 
 
 
 
7 nAChR, we examined the effect of 
cholinergic stimulation on endothelial cell activation in vitro and in vivo. Using the 
Shwartzman reaction, we observed that nicotine (2 mg/kg) and the novel cholinergic agent 
CAP55 (12 mg/kg) inhibit endothelial cell adhesion molecule expression. Using endothelial 
cell cultures, we observed the direct inhibitory effects of acetylcholine and cholinergic agents 
on tumor necrosis factor (TNF)-induced endothelial cell activation. Mecamylamine, an nAChR 
antagonist, reversed the inhibition of endothelial cell activation by both cholinergic agonists, 
confirming the antiinflammatory role of the nAChR cholinergic pathway. In vitro mechanistic 
studies revealed that nicotine blocked TNF-induced nuclear factor–
 
 
 
B nuclear entry in an 
inhibitor 
 
 
 
B (I
 
 
 
B)
 
 
 
- and I
 
 
 
B
 
 
 
-dependent manner. Finally, with the carrageenan air pouch 
model, both vagus nerve stimulation and cholinergic agonists significantly blocked leukocyte 
migration in vivo. These findings identify the endothelium, a key regulator of leukocyte 
trafficking during inflammation, as a target of anti-inflammatory cholinergic mediators.
 
Endothelial cells play a critical role in host im-
mune responses during inflammation and in-
fection. Proinflammatory molecules produced
during infection, sepsis, and other inflamma-
tory disease states activate the endothelium (for
review see reference 1). When activated, the
endothelium expresses multiple adhesion mol-
ecules and additional proinflammatory mediators.
A critical function of the activated endothelium
during inflammation is to coordinate the migra-
tion of peripheral blood leukocytes to sites of
inflammation/infection. Cell-associated adhe-
sion molecules, such as E-selectin, intercellular
adhesion molecule 1 (ICAM-1), and vascular
cell adhesion molecule 1 (VCAM-1), and che-
mokines expressed by the endothelium facilitate
the rolling, adhesion, activation, and emigration
of circulating leukocytes across the endothelial
cell barrier to the site of infection or inflam-
mation. Endothelial cell activation and leuko-
cyte recruitment are critical for the effective
elimination of invading pathogens. However,
excessive leukocyte accumulation during infec-
tion and inflammation mediated by the overex-
pression (or sustained expression) of adhesion
molecules by the endothelium can lead to tissue
damage. By contrast, insufficient endothelial
cell activation and subsequent impaired immune
cell trafficking can result in host immunosuppres-
sion. Thus, the regulation of endothelial cell
activation must be controlled precisely. Numer-
ous therapeutic agents attenuate the excessive
activation of the endothelium. Interestingly,
dexamethasone inhibits LPS-induced endo-
thelial cell adhesion molecule expression but
not the cellular activation induced by TNF (2).
The recently described cholinergic anti-
inflammatory pathway is a physiological mecha-
nism that modulates host inflammatory responses
 
R.W. Saeed and S. Varma contributed equally to this work.
 
†
 
Dr. Varma died on 5 January 2004.
 
CORRESPONDENCE
Christine N. Metz: 
cmetz@nshs.edu
 
Abbreviations used: ACh, acetyl-
choline; 
 
 
 
-BGT, 
 
 
 
-bungaro-
toxin; CAP55, cholinergic ago-
nist P55; HRP, horseradish 
peroxidase; HuMVECs, human 
microvascular endothelial cells; 
ICAM-1, intercellular adhesion 
molecule 1; I
 
 
 
B, inhibitor 
 
 
 
B; 
MCP-1, monocyte chemoattrac-
tant protein 1; MIP-1
 
 
 
, macro-
phage inflammatory protein 1
 
 
 
; 
MIP-1
 
 
 
, macrophage inflamma-
tory protein 1
 
 
 
; MIP-2, macro-
phage inflammatory protein 2; 
nAChR, nicotinic acetylcholine 
receptor; VCAM-1, vascular cell 
adhesion molecule 1; VNS, 
vagus nerve stimulation. 
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via cholinergic mediators or by electrical stimulation of the
vagus nerve (for review see reference 3). Studies describing
the cholinergic antiinflammatory pathway show that acetyl-
choline (ACh), the primary neurotransmitter released by the
vagus nerve, and nicotinic acetylcholine receptor (nAChR)
agonists block TNF production by LPS-stimulated mac-
rophages (4) via the 
 
 
 
7 nAChR (5). Stimulation of the vagus
nerve releases ACh, leading to suppressed TNF production
in vivo (4) via the 
 
 
 
7 nAChR (5). Like ACh, nicotine, a
nicotinic cholinergic agonist, binds and activates nAChRs
(6) and exerts antiinflammatory activities in vitro and in vivo
(4, 7–9). Nicotine also has been shown to be an effective
treatment in experimental animal models of ulcerative colitis
(9, 10) and sepsis (11). Recent studies by Wang and cowork-
ers (5) revealed that the antiinflammatory activity of nicotine
after LPS treatment is mediated via the 
 
 
 
7 nAChR ex-
pressed by macrophages. Unfortunately, the use of nicotine
as a therapeutic agent is limited by its toxicity.
Endothelial cells express nAChRs (12–16). Previously it
was unknown whether ACh and cholinergic agonists modu-
late endothelial cell activation and leukocyte recruitment.
Herein, we report that human microvascular endothelial
cells (HuMVECs) express 
 
 
 
7 nAChR, and that nicotine, a
novel cholinergic agonist (CAP55), and vagus nerve stimula-
tion (VNS) inhibit leukocyte recruitment during local in-
flammation via the cholinergic pathway. This effect is medi-
ated, in part, by blocking endothelial cell activation via
NF
 
 
 
B, suggesting that the endothelium is a target of the
cholinergic antiinflammatory pathway.
 
RESULTS
nAChR agonists suppress endothelial cell activation in vivo
 
Activation of the endothelium, characterized by increased
cell surface adhesion molecule expression, is a critical com-
ponent for leukocyte recruitment during inflammation. The
localized Shwartzman reaction is characterized by endothe-
lial cell activation, with increased and sustained expression of
adhesion molecules (17). We observed that nicotine signifi-
cantly decreased both VCAM-1 mRNA and E-selectin
mRNA expression by the endothelium (Fig. 1 A), as deter-
mined by quantitative real-time RT-PCR methods. Immu-
nostaining methods showed that treatment with nicotine (2
mg/kg) reduced VCAM-1 and E-selectin protein expression
by the endothelium (Fig. 1, B and C) when compared with
vehicle-treated animals. Enumeration of VCAM-1 and
E-selectin staining revealed that nicotine-treated sections had
 
 
 
5 (
 
 
 
2) and 3 (
 
 
 
2) positive capillaries/vessels per field, re-
spectively, whereas saline-treated animals had 10 (
 
 
 
3) and 8
(
 
 
 
3), respectively. These data show that the cholinergic ag-
onist nicotine significantly reduced endothelial cell activa-
tion in vivo.
 
Chemical structure and characterization of CAP55
 
One of the significant disadvantages of nicotine as a thera-
peutic agent is its toxicity. Therefore, a library of com-
pounds was generated to produce novel cholinergic agonists.
When the inhibition of TNF production by LPS-stimulated
macrophages was used a screening assay, CAP55 emerged as
a lead cholinergic compound. The chemical structure of nic-
otine and CAP55 are shown in Fig. 2 A. Both nicotine and
Figure 1. Cholinergic agonists block endothelial cell activation in 
vivo. Mice previously injected with a preparatory dose of LPS in the ear 
received vehicle (saline), nicotine (2 mg/kg), or CAP55 (12 mg/kg) 15 min 
before systemic LPS challenge (Shwartzman reaction model). Five h after 
LPS challenge, mouse ears were analyzed for (A) VCAM-1 and E-selectin 
mRNA expression by quantitative RT-PCR. Data are shown as the average 
relative expression of VCAM-1 and E-selectin mRNA copy number (normalized 
to GAPDH) in samples obtained from saline- versus nicotine-treated mice. 
*, P   0.05 comparing nicotine treated vs. saline treated using the Student’s 
t test. (B) VCAM-1 and (C) E-selectin expression within the ears by immu-
nostaining methods (arrows indicate vessels). 
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CAP55 significantly inhibit TNF production by LPS-stimu-
lated macrophages (Fig. 2 B). Based on the antiinflammatory
activity of this cholinergic compound, we investigated the
effect of CAP55 (12 mg/kg) on endothelial cell activation in
vivo using the local Schwartzman reaction. Similar to our
results with nicotine, CAP55 inhibited both VCAM-1 and
E-selectin expression by the endothelium in vivo by 
 
 
 
50%
(Fig. 1, B and C).
 
ACh and nAChR agonists inhibit TNF-induced adhesion 
molecule expression by HuMVECs
 
To determine the direct effect of cholinergic mediators on
endothelial cell activation, we treated HuMVECs with vehi-
cle, ACh, nicotine, or CAP55 before stimulation with TNF.
Treatment of HuMVECs with TNF alone significantly in-
duced adhesion molecule expression over control (Fig. 3 A).
Treatment of endothelial cell cultures with ACh significantly
abrogated TNF-induced expression of E-selectin, ICAM-1,
and VCAM-1, in a dose-dependent manner (up to 60–70%).
Similarly, nicotine reduced TNF-mediated adhesion mole-
cule expression by HuMVECs by 60–70% (Fig. 3, B and D).
The novel nAChR agonist, CAP55, blocked TNF-induced
ICAM-1 expression by the endothelium by 
 
 
 
40–50%, (Fig.
3 C). No cytotoxicity was observed with ACh or the cho-
linergic agonists at the concentrations used (unpublished
data), indicating that the effect was specific. In addition,
these cholinergic agonists did not induce endothelial cell ad-
hesion molecule expression in the absence of TNF (unpub-
lished data).
 
HuMVECs express the cell surface 
 
 
 
7 nAChR
 
The 
 
 
 
7 nAChR expressed by macrophages mediates the anti-
inflammatory effects of cholinergic stimulation in vitro and in
vivo (5). Using RT-PCR and Western blotting methods, we
observed 
 
 
 
7 nAChR mRNA and protein expression by cul-
tured HuMVECs (Fig. 4, A and B). Further RT-PCR studies
revealed the expression of 
 
 
 
5 and 
 
 
 
9 nAChR mRNA (un-
published data). We confirmed the surface expression of the
 
 
 
7 nAChR by HuMVECs using FITC-labeled 
 
 
 
-bungaro-
toxin (
 
 
 
-BGT), a selective 
 
 
 
7 nAChR antagonist (Fig. 4 C).
Competition studies using nicotine and unlabeled 
 
 
 
-BGT sig-
nificantly reduced FITC–
 
 
 
BGT binding by HuMVECs.
 
Mecamylamine blocks the effects of cholinergic agonists on 
adhesion molecule expression
 
To test whether the inhibitory effect of nicotine and CAP55
on endothelial cell activation in vitro was mediated through
the cholinergic pathway, we used mecamylamine, a nonse-
lective nAChR antagonist. Addition of mecamylamine at-
tenuated the effects of nicotine and CAP55 on TNF-induced
ICAM-1 expression (Fig. 5, A and B). These data suggest
that the suppressive effect of nicotine and CAP55 on TNF-
mediated endothelial cell activation is mediated, in part, through
the nAChR pathway.
 
ACh and nAChR agonists reduce TNF-induced chemokine 
production by endothelial cells
 
The endothelium is not only a target of proinflammatory me-
diators; it also is a source of proinflammatory molecules such
as chemokines. Treatment of HuMVEC monolayers with
TNF induced the production of IL-8, monocyte chemoat-
tractant protein 1 (MCP-1), and regulated on activation, nor-
mal T cell expressed and secreted (RANTES) (Fig. 6, A and
B), but not macrophage inflammatory protein 1
 
 
 
 (MIP-1
 
 
 
)
or MIP-1
 
 
 
 (not depicted). ACh and the nAChR agonist, nic-
otine, suppressed MCP-1, RANTES, and IL-8 production
(
 
 
 
50%
 
)
 
 by TNF-induced HuMVECs (Fig. 6, A and B). Sim-
ilarly, the novel nAChR agonist, CAP55, blocked IL-8 pro-
duction by TNF-treated HuMVECs by 
 
 
 
50% (Fig. 6 C).
 
Treatment of endothelial cells with nicotine blocks 
leukocyte binding in vitro
 
To confirm that impaired adhesion molecule expression ob-
served with cholinergic agonists reduced leukocyte adhe-
sion, we performed in vitro binding assays. Treatment of the
HuMVECs with TNF increased the binding of previously
labeled monocytes and neutrophils by approximately fivefold
(Fig. 7, A and B) when compared control cultures. Nicotine
pretreatment significantly abrogated TNF-induced mono-
cyte and neutrophil binding (Fig. 7). These data suggest that
nicotine reduced the adhesion of leukocytes to HuMVECs
and support the hypothesis that cholinergic agonists decrease
endothelial cell activation.
Figure 2. Structure and antiinflammatory activity of CAP55 in vitro. 
(A) Chemical structure of nicotine and CAP55. (B) CAP55 and nicotine inhibit 
TNF production by LPS-stimulated macrophages in vitro. Experiments
were performed as described in Materials and methods. *, P   0.05; 
**, P   0.001 comparing CAP55   LPS– or nicotine   LPS–treated cells 
versus LPS-treated cells alone, as determined using the Student’s t test. 
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Nicotine inhibits NF-
 
 
 
B nuclear localization
 
Because the NF-
 
 
 
B pathway regulates many genes involved
in TNF-mediated endothelial cell activation, we examined
the effect of nicotine on NF-
 
 
 
B and inhibitor 
 
 
 
B (I
 
 
 
B) fam-
ily members. We found that nicotine (10
 
 
 
6
 
–10
 
 
 
7
 
M) reduced
the nuclear translocation of NF-
 
 
 
B in HuMVECs after a 15-
min TNF treatment (Fig. 8 A). Further studies showed that
nicotine increased I
 
 
 
B
 
 
 
 (Fig. 8 B) and I
 
 
 
B
 
 
 
 (Fig. 8 C) levels
in the cytoplasm, when compared with control cells.
 
Cholinergic stimulation blocks leukocyte migration during 
inflammation in vivo
 
Based on our findings that cholinergic agonists blocked en-
dothelial cell activation and leukocyte binding, we next ex-
amined the effect of cholinergic agonists on leukocyte re-
cruitment in vivo. Using the air pouch model of leukocyte
migration, we administered either vehicle or cholinergic ag-
onists before carrageenan challenge. We observed that nico-
tine (2 mg/kg) significantly reduced leukocyte trafficking by
 
 
 
60% compared with vehicle treatment (Fig. 9 A). CAP55
(4 or 12 mg/kg, i.p.) blocked leukocyte recruitment induced
by carrageenan by 55% and 62%, respectively, when com-
pared control (Fig. 9 B).
Administration of mecamylamine, a negative allosteric
modulator of the nAChR, significantly attenuated the accu-
mulation of leukocytes induced by cholinergic agonists (Fig.
9, A and B, insets). These data demonstrate that both nicotine
and CAP55 block leukocyte migration during acute inflam-
matory responses, predominantly via a cholinergic pathway.
Previous studies describe the antiinflammatory effects of
VNS mediated through the cholinergic pathway, specifically
through the 
 
 
 
7 nAChR (5). Like cholinergic agonists, VNS
reduced leukocyte recruitment by 60% compared with
sham-operated animals (Fig. 9 C). These data further suggest
that cholinergic activation suppresses host inflammatory re-
sponses, (i.e., leukocyte migration across the endothelium).
Figure 3. ACh and cholinergic agonists block adhesion molecule 
expression by TNF-treated endothelial cells in vitro. Confluent mono-
layers of HuMVECs were untreated, treated with TNF (1 ng/ml) alone or 
were treated with (A) ACh, (B) nicotine, or (C) CAP55 before TNF stimula-
tion (1 ng/ml). Cell surface expression of ICAM-1 ( ), E-selectin ( ), or 
VCAM-1 ( ) was determined using a cell-based ELISA method. 100% 
represents 0.55 (0.04), 1.12 (0.05), and 0.864 (0.03) OD ( SD) at 450 for 
E-selectin, ICAM-1, and VCAM-1, respectively. *, P   0.05, **, P   0.01 
comparing treatment   TNF versus TNF alone using the Student’s t test. 
Data are shown as the percent control ( SD), with TNF alone as control. 
(D) ICAM-1 expression was assessed using flow cytometry methods (mean 
fluorescence intensity, MFI) using ICAM-1–specific antibodies: (1) untreated 
cells (isotype control), MFI   29.6; (2) untreated cells, MFI   164; (3) 
nicotine (10 6 M)   TNF (1 ng/ml), MFI   380; and (4) TNF (1 ng/ml) 
alone, MFI   677. 
JEM VOL. 201, April 4, 2005
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Cholinergic agonists suppress production of inflammatory 
mediators found in the pouch fluid
The synthesis of inflammatory mediators by immune cells
within the pouch is a critical step in promoting leukocyte re-
cruitment to inflamed tissues. Because cholinergic agonists
inhibited the accumulation of leukocytes in the air pouch
model, we next analyzed the pouch fluids for inflammatory
mediators. Pouch TNF levels peak 2 h after carrageenan
challenge and then decline to baseline 24–48 h after chal-
lenge (18). Administration of nicotine blocked TNF pro-
duction in the pouch by 30% when compared with vehicle-
treated control animals. CAP55 reduced TNF levels by 40%
when compared with vehicle-treated controls (100  7%
control vs. 60  11%). Neutrophils and monocytes, the pre-
dominant inflammatory cells within the pouch, express
chemokine receptors that mediate their recruitment by spe-
cific chemokines (MIP-2 and MCP-1, respectively). We ob-
served that nicotine (2 mg/kg) and CAP55 (12 mg/kg) sig-
nificantly reduced the pouch fluid levels of MCP-1 by 20%
and 30%, respectively. By contrast, MIP-2, MIP-1 , and
MIP-1  levels were only slightly decreased by nicotine and
CAP55 treatments.
DISCUSSION
Herein we report that cholinergic signals inhibit endothelial
cell inflammatory responses in vitro and in vivo. Using the
localized Shwartzman reaction model, characterized by sus-
tained E-selectin and VCAM-1 expression (17), we showed
that nicotine (2 mg/kg) significantly suppresses endothelial
cell activation in vivo (Fig. 1). Although nicotine treatment
had no effect on complete blood cell (wet) and differential
(absolute) counts when compared with saline treatment in
these studies, this therapeutic dose is close to the LD50 of
nicotine in mice (3–9 mg/kg). Therefore, we examined the
effect of a novel cholinergic agonist with antiinflammatory
activity, CAP55 (LD50  40 mg/kg), on endothelial cell acti-
vation in this model (Fig. 2). At 12 mg/kg, CAP55 was very
effective in inhibiting endothelial cell activation in vivo
(Fig. 1). Because of its reduced toxicity, CAP55 offers thera-
peutic advantages over nicotine.
To confirm the direct effects of ACh and cholinergic
agents on endothelial cell activation in vitro, we used HuM-
VECs. ACh, nicotine, and CAP55 significantly blocked
TNF-induced adhesion molecule expression (Fig. 3) and
chemokine expression (Fig. 6) by HuMVECs in a dose-
dependent manner. Consistent with these observations, we
found that nicotine treatment of the endothelium reduced
leukocyte/endothelial cell adhesion (Figs. 7, A and B). It has
been postulated that, as leukocytes roll across the vasculature,
inflammatory mediators present on the surface of the endo-
thelium, such as chemokines, progressively activate them (19)
and that, upon binding to adhesion molecules, neutrophils re-
ceive signals and become activated (20, 21). Neutrophil acti-
vation allows their firm adhesion required for successful trans-
Figure 4. HuMVECs express the  7 nAChR. The expression of  7 
nAChR by HuMVECs (EC1, EC2) was assessed by (A) RT-PCR and (B) West-
ern blotting methods. (C) HuMVECs bind  -BGT-FITC (0–2.5  g), a specific 
 7 nAChR antagonist, as determined by flow cytometry.
Figure 5. Nicotine and CAP55 block TNF-induced adhesion mole-
cule expression in vitro via the nAChR pathway. HuMVECs were un-
treated, treated with TNF (1 ng/ml) alone, or treated with mecamylamine 
(Mec, 2  M) before (A) nicotine (10 6–10 7 M) or (B) CAP55 (CAP55, 
10 6–10 7 M) plus TNF (1 ng/ml) for 18 h. ICAM-1 expression (black bars) 
was determined using a cell-based ELISA technique. Data are shown as the 
percent control ( SD), with TNF alone as control. 100% represents 0.574 
(0.04) and 0.497 (0.04) OD 450 for the nicotine and CAP55 sets, respectively. 
*, P   0.05; **, P   0.01, comparing treatment plus TNF versus treatment 
plus mecamylamine plus TNF using the Student’s t test.CHOLINERGIC AGONISTS BLOCK ENDOTHELIAL CELL ACTIVATION | Saeed et al. 1118
migration during inflammation (22). Therefore, if cholinergic
agonists inhibit the binding of immune cells to the endothe-
lium, the subsequent steps of emigration and activation should
be impaired. We chose 1 ng/ml TNF for our in vitro assays
because this dose is below the saturating dose (10 ng/ml) that
induces maximal adhesion molecule expression in our in vitro
assays. This dose allows the detection of an increase or a de-
crease in endothelial cell activation by specific agonists. In ad-
dition, this is a biologically relevant dose of TNF, i.e., serum
TNF levels of 1 ng/ml are fairly high but are achievable.
To examine the effect of nicotine on TNF-induced ad-
hesion molecule expression in vivo, mice were injected with
rTNF (1  g s.c.) into the pinnae of the ear, and 2 h after
treatment E-selectin expression was examined by quantita-
tive RT-PCR. We observed that nicotine reduced E-selec-
tin mRNA expression by 50% (relative to GAPDH). These
data are consistent with our in vitro results using TNF and
support the hypothesis that nicotine acts on endothelial cells
to down-regulate TNF-induced inflammatory responses in
vivo. The antiinflammatory activities of nicotine have been
previously reported: nicotine (a) inhibits cytokine/chemo-
kine production (4, 9, 23), (b) inhibits NF- B activation (24),
(c) abrogates T cell development and maturation (7), and (d)
inhibits neutrophil and monocyte killing function (25). In
animal models, nicotine suppresses the progression of exper-
imental ulcerative colitis (9, 10) and cutaneous inflammation
(26) and improves survival during endotoxemia and sepsis
(11). In addition, nicotine has been used successfully in the
treatment of human ulcerative colitis (27–29). However, the
precise mechanism by which nicotine inhibits inflammation
in these models is not completely understood.
Figure 6. ACh and cholinergic agonists block chemokine produc-
tion by TNF-treated HuMVECs. HuMVECs were untreated, treated with 
TNF (1 ng/ml) alone, or treated with (A) ACh, (B) nicotine, or (C) CAP55 before 
TNF stimulation (1 ng/ml) for 18 h. The production of IL-8 ( ), MCP-1 ( ), 
or RANTES ( ) was determined by ELISA. Data are shown as the percent 
control ( SD), with TNF alone as control. 100% represents 18,848 (430), 
63,436 (9,194), 3,122 (64) pg/ml ( SD) for IL-8, MCP-1, and RANTES, 
respectively. *, P   0.05; **, P   0.01 comparing treatment plus TNF versus 
TNF alone using the Student’s t test.
Figure 7. Nicotine blocks monocyte and neutrophil adhesion to 
HuMVECs. HuMVECs were untreated, treated with TNF alone, or treated 
with nicotine (Nic, 10 7 M) before TNF stimulation (1 ng/ml) or no TNF 
stimulation. HuMVECs were washed and incubated with either (A) human 
monocytes or (B) neutrophils (previously labeled with Calcein AM) for 0.5 h. 
After washing, bound leukocytes were quantified using a cytofluorescence 
assay method. The data are shown as the number of cells bound to the 
HuMVEC monolayers expressed as percent control ( SD), with the control 
being TNF-treated HuMVECs alone. 100% represents  16% (or 3.2   104) 
and 27% (or 5.4   104) of input monocytes and neutrophils, respectively 
(based on a standard curve of labeled cells). *, P   0.05 nicotine plus TNF 
versus TNF alone using the Student’s t test.JEM VOL. 201, April 4, 2005 1119
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Wang and coworkers (5) recently identified the  7
nAChR expressed by macrophages as the target of antiin-
flammatory cholinergic mediators, including nicotine. Inter-
estingly, the  7 nAChR receptor has been implicated in in-
flammation in chronic inflammatory pain transmission in
vivo (30). Numerous studies have identified the expression of
nAChRs (including  2,  3,  4,  5,  7,  2, and  4 subunits)
by several endothelial cell types, including cerebral (12), aor-
tic (13, 14), umbilical vein (15), and coronary microvascular
(16) endothelial cells. In this report, we show the expression
of  7 nAChR mRNA and protein by HuMVECs (Fig. 4, A
and B) and binding of the  7-nAChR selective antagonist,
 -BGT, by HuMVECs (Fig. 4 C). Nicotine exerts diverse
and numerous activities on resting endothelial cells, including
proliferative (31) and apoptotic effects (32). Interestingly, the
 7 nAChR expressed by the endothelium plays a role in nic-
otine-mediated angiogenesis (15). This report is the first re-
port to describe the effects of ACh and cholinergic agonists
on endothelial cell inflammatory responses.
To demonstrate that nicotine and CAP55 blocked en-
dothelial cell activation via nAChRs, we used mecamy-
lamine, a nonselective and noncompetitive nAChR blocker
that occupies the ion channel and not the nicotine-binding
site. The in vitro and in vivo nAChR signaling by nicotine
Figure 8. Nicotine blocks NF- B nuclear translocation in an I B - 
and I B -dependent manner. HuMVECs were either untreated or 
treated with nicotine (10 6–10 7 M) before TNF stimulation or no stimu-
lation. Cytoplasmic and nuclear fractions were isolated 15 min after TNF 
addition. Samples were electrophoresed, transferred, and Western blotted 
using (A) NF- B, (B) I B , or (C) I B  antibodies. Lamin A/C and  -actin 
were used as controls for loading the nuclear and cytoplasmic fractions, 
respectively. Data are also shown as the ratio of NF- B, I B , or I B  to 
control (nuclear or cytoplasmic) protein.
Figure 9. Cholinergic stimulation blocks leukocyte recruitment in 
vivo. (A) The effect of vehicle (saline) or nicotine (0.2 and 2 mg/kg, i.p.) on 
leukocyte recruitment was examined using the carrageenan air pouch 
model. (B) The effect of saline or CAP55 (1, 4, or 12 mg/kg, i.p.) on leukocyte 
recruitment. (A, inset) Mice were pretreated with mecamylamine (Mec, 200 
 g/mouse) before treatment with nicotine (2 mg/kg) or (B inset) CAP55 (12 
mg/kg). (C) VNS blocks leukocyte recruitment (compared with sham surgery 
treatment) using the carrageenan air pouch model. The data are shown as 
the average number of inflammatory cells per pouch (  SEM), presented 
as percent control vehicle-treated animals as the control. 100% represents 
2.7   106, 1.4   106, and 1.8   106 cells per pouch in the groups of animals 
treated with nicotine, CAP55, and VNS, respectively. *, P   0.05; **, P  0.01; 
***, P   0.001, using the Student’s t test comparing treatment versus 
vehicle or treatment versus treatment plus mecamylamine (insets).CHOLINERGIC AGONISTS BLOCK ENDOTHELIAL CELL ACTIVATION | Saeed et al. 1120
and other cholinergic agonists can be reversed by mecamy-
lamine (16, 33, 34). Mecamylamine reversed the inhibitory
effects of both nicotine and CAP55 on endothelial cell acti-
vation in vitro (Fig. 5, A and B), and in vivo (Fig. 9, insets),
suggesting that nicotine and CAP55 exert their antiinflam-
matory effects on the endothelium via the nAChR pathway.
The NF- B/Rel family of transcription factors regulates
the expression of many genes that control endothelial cell
activation during inflammation. The effect of nicotine on
NF- B activation in the U937 monocytic cell line was pre-
viously identified (24). We found that nicotine reduced the
nuclear import of NF- B (p65 Rel A) after TNF stimulation
(Fig. 8 A) and increased cytoplasmic levels of the I B pro-
teins (  and  ) that bind and retain NF B in the cytoplasm
(Fig. 8, B and C). I B , a relatively newly identified mem-
ber of the I B family (35, 36), was recently shown to play a
functional role in endothelial cell activation (37). I B levels
were assessed at 15 min after TNF addition (before the re-
synthesis of I Bs), suggesting that nicotine reduces I B deg-
radation. Interestingly, nicotine-treated endothelial cells (in
the absence of TNF) had increased cytoplasmic levels of I B
proteins. Future studies will focus on the effect of cholin-
ergic stimulation (by agonists and electrical stimulation) on
NF- B activation in vivo. Another proposed mechanism by
which cholinergic agonists inhibit endothelial cell activation
is by inducing the shedding of TNF receptors. We found
that nicotine did not down-regulate TNF receptor (I and II)
surface expression in the presence or absence of TNF.
Although human endothelial cells respond to cholinergic
mediators in vitro, this finding does not establish that similar
responses occur in vivo or occur to the same degree. There-
fore, we next examined whether the effect of cholinergic
agents and cholinergic stimulation on endothelial cell activa-
tion impaired in vivo leukocyte trafficking. Using the carra-
geenan air pouch model, we observed that cholinergic ago-
nists (nicotine and CAP55) suppress leukocyte migration
during inflammation in vivo (Fig. 9, A and B). Mecamy-
lamine antagonizes many of the effects of nicotine (38–40)
and of epibatidine, another potent nAChR agonist shown to
suppresses inflammatory pain in animals induced by kaolin
and carrageenan (41). Administration of mecamylamine
blocked the inhibitory actions of nicotine and CAP55 (Fig.
9, A and B, insets), suggesting that this effect, in part, is me-
diated through the nAChR cholinergic pathway. Further
studies using VNS, a method previously shown to activate
the cholinergic antiinflammatory pathway in rodents and to
suppress proinflammatory cytokine production in vivo (4,
5), revealed that VNS significantly reduces leukocyte re-
cruitment in vivo (by  60%) (Fig. 9 C).
These studies demonstrating the suppressive effects of nic-
otine and CAP55 on endothelial cell activation and leukocyte
recruitment highlight the potential therapeutic use of cholin-
ergic agonists in cases of excessive inflammatory responses by
the endothelium. In addition to immunomodulation by cho-
linergic agonists, recent studies in experimental animals reveal
that electrical stimulation of the efferent vagus nerve (which
releases the neurotransmitter acetylcholine) modifies host in-
flammatory responses (for review see reference 3). Activation
of this neural cholinergic antiinflammatory pathway via vagus
nerve stimulation reduces both systemic and local inflamma-
tion in vivo (4, 42). Our studies demonstrate the antiinflam-
matory effects of VNS and cholinergic agonists on endothe-
lial cell inflammatory responses in vivo and identify the
endothelium as a potential cholinergic target.
MATERIALS AND METHODS
Reagents
ACh, pyrostigmine bromide (acetylcholinesterase inhibitor),   carrageenan
(type IV), LPS from Escherichia coli (0111:B4), and nicotine were purchased
from Sigma-Aldrich. Mecamylamine hydrochloride was purchased from
ICN Biomedicals. CAP55, a novel cholinergic agonist, was provided by Y.
Al-Abed (Institute for Medical Research at North Shore-LIJ).
Animal models of leukocyte recruitment and endothelial 
cell activation
All experimental procedures using laboratory animals were reviewed and
approved by the Institutional Animal Care and Use Committee of the Insti-
tute for Medical Research at North Shore-LIJ.
Localized Shwartzman reaction model. The localized Shwartzman
reaction was performed as previously described (17). Briefly, female BALB/c
mice (22–26 g, Taconic) were injected with i.p. saline, nicotine, or CAP55
(i.p., at the indicated doses), and 20  g LPS (preparatory dose) was injected
s.c. into the pinnae of the ear. One day later, four mice per group were in-
jected with vehicle (saline), nicotine, or CAP55 (i.p. at the indicated doses)
15 min before challenge with LPS (150  g, i.p.) to generate a localized vas-
culitic reaction. Five hours later, mice were killed by carbon dioxide
asphyxiation. The ears were excised, flash-frozen in liquid nitrogen, and
stored at  80 C for immunostaining and quantitative RT-PCR analyses.
Each experiment was repeated twice.
Carrageenan air pouch model. The carrageenan air pouch model was
performed as previously described (18). To generate dorsal air pouches, Swiss
Webster mice (26–33 g, Taconic) were anesthetized (ketamine/xylazine) on
days zero and 3, and 6 ml of sterile air was injected s.c. to form a cavity. On
day 6, animals received either vehicle (saline) or nAChR agonist (nicotine or
CAP55 diluted in saline) i.p. at the indicated concentrations, and 15 min
later 1% carrageenan was injected into the preformed air pouch. In one series
of experiments, mecamylamine (200  g/mouse, PBS) was injected into the
pouch 5 min before saline, nicotine, or CAP55 injection. In another series of
experiments, the effect of VNS (performed as described in reference 5, ex-
cept that electrical stimulation was applied for 2 min) on leukocyte recruit-
ment was compared with sham surgery. The animals were killed by carbon
dioxide asphyxiation 6 h later, and the cellular infiltrate and fluid exudates
were collected as previously described (43). TNF, prostaglandin E2, MCP-1,
MIP-2, MIP-1 , and MIP-1  levels in the pouch fluids were determined by
ELISA. The collected cells (RBC-free) were counted by hemocytometer
and by using a flow cytometry method (44). Each experiment was repeated
at least twice. Data showing the inhibitory effect of cholinergic agonists on
leukocyte recruitment to the pouch are shown as percent control (mean  
SEM, with vehicle-treated as control). In one series of experiments, blood
was drawn from killed mice by cardiac puncture and analyzed for complete
blood cell (wet) and differential (absolute) counts by Ani Lytics, Inc.
Histological analyses of ears for inflammatory cell accumulation 
and VCAM-1 and E-selectin expression (Shwartzman reaction)
Ear sections (5  ) from the Shwartzman reaction were stained using
VCAM-1 and E-selectin antibodies, according to the manufacturer’s rec-JEM VOL. 201, April 4, 2005 1121
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ommendations (BD Biosciences), using anti–mouse IgG-horseradish perox-
idase (HRP) and diaminobenzidine substrate and counterstained with he-
matoxylin-eosin. Three fields per section (three sections per sample) were
assessed and scored as the average number ( SD) of VCAM-1– or E-selec-
tin–positive capillaries/vessels. Representative slides were photographed at
magnifications of 20 and 100.
Analysis of VCAM-1 and E-selection mRNA expression by 
quantitative RT-PCR
Frozen ear tissues were homogenized. Total RNA was isolated using an
RNeasy kit and QIAshredder mini spin columns (QIAGEN) and treated
with DNase to remove genomic contamination (QIAGEN). The relative
expression of VCAM-1 and E-selectin mRNA was determined by quantita-
tive real-time PCR using TaqMan technology using the Eurogentec quan-
titative RT-PCR mastermix and the Prism 7700 sequence detection system
(Applied Biosystems). Optimal concentrations of primers, probes, and
the RNA were standardized. VCAM-1 primers, forward, 5 -CTGC-
TCAAGTGATGGGATACCA-3 , reverse, 5 -AGGCTGCAGTTCC-
CCATTATT, and the VCAM-1 TaqMan probe, 5 -TCCCAAAATCCT-
GTGGAGCAGACA-3  were added at final concentrations of 900 nM and
150 nM, respectively. E-selectin primers, forward, 5 -CCGTCCCTTGG-
TAGTTGCAC-3 , reverse, 5 -CAAGTAGAGCAATGAGGACGATGT-
3  and the E-selectin TaqMan probe, 5 -TTCTGCGGCAGGAACCT-
CACTCCT-3  were added at final concentrations of 500 nM and 100 nM,
respectively. Mouse GAPDH was used as an internal control gene; mouse
GAPDH primers, forward, 5 -TGTGTCCGTCGTGGATCTGA-3 , re-
verse, 5 -CCTGCTTCACCACCTTCTTGA-3  and the GAPDH Taq-
Man probe, 5 -CCGCCTGGAG-AAACCTGCCA-3  were added at final
concentrations of 500 nM and 100 nM, respectively. The thermal cycler
conditions were 35 cycles of 94 C for 20 s, 55 C for 20 s, and 72 C for 30 s
Data were analyzed using Sequence Detection System software, version
1.9.1. Relative expression of VCAM-1 and E-selectin gene in ears obtained
from mice treated with nicotine was calculated in comparison with vehicle-
treated control samples using the  - -Ct method (User Bulletin 2, Applied
Biosystems). All samples were run in duplicate.
Cells and cell culture
Macrophage studies. Human macrophages were isolated, cultured, and
used as previously described (5). Macrophages were treated with nicotine,
CAP55, or left untreated before stimulation with 100 ng/ml LPS. After a 4-h
stimulation period, culture supernatants were collected and assayed for TNF
levels using standard ELISA methods (R&D Systems and J. Han [Institute for
Medical Research of North Shore-LIJ]). Data are shown as pg/ml TNF  SD.
Endothelial cells. Primary cultures of adult dermal HuMVECs were ob-
tained from Clonetics (division of BioWhittaker) and were maintained in com-
plete growth media (Clonetics). Experiments were initiated using synchronized
confluent monolayers (passages 4–8). Parallel sets of cells were assessed using
(3-4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolrum bromide and neutral red
staining techniques as previously described (45, 46). TNF receptor expression
by HuMVECs was assessed using the TNFR Fluorokine kit (R&D Systems). 
 7nAChR expression and  -BGT binding by HuMVECs
Analysis of  7 nAChR mRNA expression. Total RNA was extracted
from confluent monolayers of HuMVECs using RNAzol (Teltest Inc.).
The cDNA was prepared from 1  g of RNA using 0.25 ng of oligo-(dT)12-18
and moloney murine leukemia virus RT (Grand Island Biological Com-
pany). 2  l aliquots of cDNA were amplified by PCR using Supermix
(Grand Island Biological Company) in a thermal cycler (model 9600, Perkin-
Elmer) using specific primers for human  7 nAChR. The primers for hu-
man   7 nAChR were 5 -CCTGGCCAGTGTGGAG-3 (forward); 5 -
TACGCAAAGTCTTTGGACAC-3  (reverse). Amplified fragments of
expected size (414 bp) were analyzed using a 2% agarose gel and photo-
graphed over UV light.
Analysis of  7nAChR protein expression. Confluent monolayers of
HuMVEC cell lysates (20  g/lane) were separated by electrophoresis and
transferred to polyvinylidene difluoride membranes. Membranes were
probed with rabbit primary antibody specific for human  7 nAChR, fol-
lowed by incubation with HRP-conjugated goat anti–rabbit IgG and re-
vealed using ECL (Amersham Biosciences).
 -BGT-FITC binding assays. HuMVECs were harvested using En-
zyme Free Dissociation Buffer (Grand Island Biological Company), and
 2   105 cells per condition were incubated with FITC– -BGT (0–2.5
 g; Molecular Probes, Inc.) for 45 min in FACS buffer (PBS containing 2%
BSA and 0.1% sodium azide) at 4 C in the dark. Washed cells were ana-
lyzed by flow cytometry (FACSCalibur; BD Biosciences). Data were col-
lected and analyzed using CellQuest software (BD Biosciences). Each ex-
periment was repeated twice, with similar results.
Analysis of adhesion molecule expression
Endothelial cell surface expression of ICAM-1, VCAM-1, and E-selectin
was determined using a cell-based ELISA, as previously described (47). In
brief, G0/G1 synchronized HuMVECs grown in 96-well plates were prein-
cubated with either ACh (plus pyrostigmine bromide), an acetylcholinest-
erase inhibitor at 50  g/ml) or nAChR agonists (as indicated in the figure
legends) for either 5 min (ACh) or 30 min (nAChR agonists) before the ad-
dition of 1 ng/ml TNF. After an overnight culture, adhesion molecule ex-
pression was determined using ICAM-1 (Chemicon International, Inc.),
VCAM-1 (BD Biosciences), and E-selectin (BD Biosciences) antibodies
(n   4 per condition). In one series of experiments, the HuMVECs were
pretreated with 2  M mecamylamine before the addition of nicotine or
CAP55 plus 1 ng/ml TNF. In another set of experiments, HuMVECs were
grown and treated in six-well plates and assessed for ICAM-1 expression by
flow cytometry using an isotype control IgG1 or anti-ICAM-1 monoclonal
antibody (Chemicon International, Inc.), followed by anti–mouse IgG1-
FITC (BD Biosciences). Each experiment was repeated at least twice.
Analysis of chemokine production by endothelial cell cultures
Cell-free culture supernatants from the adhesion molecule assays (n   4 per
condition) were assayed for chemokines. MIP-1  and -1  were analyzed
by ELISA as previously described (48). RANTES and MCP-1 were ana-
lyzed by ELISA with antibodies (RANTES: MAB678 and AF478; MCP-1:
MAB679 and AF279) or ELISA kits (R&D Systems).
Assay for monocyte and neutrophil adhesion to HuMVECs in vitro
Immune cell isolation and labeling. Monocytes from human peripheral
blood were isolated by density-gradient centrifugation, followed by adher-
ence. Human neutrophils were isolated from fresh blood after the sedimenta-
tion of erythrocytes using dextran, followed by centrifugation through Ficoll/
Hypaque (Amersham Biosciences). Remaining RBCs were removed by hy-
potonic lysis. Monocytes and neutrophils were labeled with Calcein AM
(Molecular Probes, Inc.) according to the manufacturer’s directions. Endothe-
lial cell adhesion assays: HuMVECs grown in 96-well plates (as described in
Analysis of adhesion molecule expression) were either untreated or treated for
1 h with nicotine (10 7 M) before stimulation with 1 ng/ml TNF or no stim-
ulation. Labeled monocytes or neutrophils (2   105 cells/well) were added
5 h later to washed HuMVECs (n   4–6 replicates per sample). After 0.5 h,
nonadherent leukocytes were removed by washing three times with media. A
standard curve was made using known concentrations of labeled cells/well.
Leukocytes/well were determined by cytofluorescence using a microplate
reader (CytoFluor II, PerSeptive Biosystems). Assays were repeated twice.
Western blotting to assess NF- B nuclear translocation and I B  
and I B  levels
G0/G1 synchronized HuMVECs were treated with nicotine (10 6–10 7 M)
or left untreated for 0.5–1 h before the addition of TNF (1 ng/ml). Nuclear
and cytoplasmic extracts were prepared 0.25 h after TNF addition using theCHOLINERGIC AGONISTS BLOCK ENDOTHELIAL CELL ACTIVATION | Saeed et al. 1122
NE-PER kit (Pierce Chemical Co.). Cell lysates ( 10  g/lane) were elec-
trophoresed, transferred to polyvinylidene difluoride membranes, and
probed with antibody to NF- B (p65 (Rel A); Cell Signaling Technology,
Inc.), I B , and I B  (Santa Cruz Biotechnology, Inc.) or with antibodies
to control nuclear (Lamin A/C; Santa Cruz Biotechnology, Inc.) and cyto-
plasmic ( -actin; Chemicon International, Inc.) proteins. After incubation
with HRP-conjugated secondary antibody, specific proteins were revealed
using ECL (Amersham Biosciences). Band densities were determined using
the National Institute of Health Image Program, and the ratios of the specific/
control bands are shown.
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